Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Dexamethasone
Daratumumab
+2 more
Locations
40
United States
Univ of Colorado Cancer Center /ID# 167331
Aurora, Colorado, United States
Moffitt Cancer Center /ID# 169614
Tampa, Florida, United States
Winship Cancer Institute of Emory University /ID# 165427
Atlanta, Georgia, United States
The University of Chicago Medical Center /ID# 165429
Chicago, Illinois, United States
Beth Israel Deaconess Medical Center /ID# 210904
Boston, Massachusetts, United States
Dana-Farber Cancer Institute /ID# 166886
Boston, Massachusetts, United States
Start Date
April 2, 2018
Primary Completion Date
May 1, 2031
Completion Date
May 1, 2031
Last Updated
August 14, 2025
NCT06679101
NCT05969860
NCT06057402
NCT06383143
NCT06870760
NCT06285318
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions